Ainos, Inc.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Chun-Hsien Tsai
- Full Time Employees
- 44
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8880 Rio San Diego Drive San Diego CA United States of America 92108
- IPO Date
- Jan 8, 2021
- CIK
- 0001014763
- Website
- ainos.com
- Similar Companies
- Business
- Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Company News
Water Tower Research Highlights Growing Momentum for Ainos' Scent-Tech Solutions and Industrial SmellTech Leadership with New High-Impact Partnerships
Ainos and Solomon Partner to Bring SmellTech Across Asia's Industrial Landscape
Ainos Completes Stock Consolidation, Enters New Phase of Global Expansion and Technology Commercialization
Ainos and ASE Technology Holding Broaden Strategic Partnership to Target Deploy Up to 15,000 AI Nose Across Key Sites
Ainos Aligns Capital Structure With 2H 2025 Execution Roadmap; Announces Stock Consolidation
Ainos and Kenmec Launch Strategic Partnership to Deploy AI-Powered Scent Intelligence in Smart Factories Across Asia
Water Tower Research Spotlights Ainos' Advances and Milestones in Digital Olfaction and Healthcare: Entering Inflection Point in 2H25
Ainos Issues Mid-Year Update: Reaching Strategic Inflection in SmellTech and Immunotherapy
Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter
Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
Ainos Showcases Breakthrough AI Nose Technology at COMPUTEX 2025 with Japan's Robotics Partner
Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy
Water Tower Research Highlights Ainos' Significant Commercial Traction and Strategic Milestones Across Multiple Sectors
Ainos Reports First Quarter 2025 Financial Results
Water Tower Research Spotlights Ainos' Smell Integration in Humanoid Robot - AI Smelltech is Progressing Rapidly
Ainos and ugo Complete First Robotic Smell Integration in Japan
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan
Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling
Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025
Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose's Potential in Chip Manufacturing and More